Continuous Radiofrequency in Hip Osteoarthritis Pain: A Randomized Clinical Trial.

Launched by UNIVERSITY OF BRASILIA · Jan 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments to help people with hip osteoarthritis, which is a type of arthritis that causes pain and stiffness in the hip joint. The study will compare the effectiveness of a corticosteroid injection (a type of medication that reduces inflammation and pain) with a procedure called Conventional Radiofrequency, which targets specific nerves in the hip area to relieve pain. The goal is to see which method works better in reducing pain and improving daily activities for those suffering from this condition.

To be eligible for this trial, participants should be at least 18 years old and have been experiencing hip pain for more than six months, specifically due to osteoarthritis classified as grades II or III. However, individuals with certain conditions, such as previous hip surgery, specific types of nerve pain, or other significant health issues, won't be able to participate. Those who join the study can expect to receive one of the treatments and will be monitored to see how well it works for their hip pain and function. The trial is currently recruiting participants, and it welcomes individuals of all genders within the specified age range.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals ≥ 18 years of age, with symptomatic unilateral hip osteoarthritis, grades II and III according to the Kellgreen and Lawrance classification, hip pain for more than six months (medial, anterior, anterolateral, and/or lateral region) will be included.
• Exclusion Criteria:
• • Individuals with radiculopathy and ipsilateral irradiation, osteonecrosis of the femoral head, previous arthroplasty on the hip to be studied or surgical scar that could lead to changes in the anatomy of the hip, cases of high dislocation of the hip, pain exclusively in the posterior region, symptomatic ipsilateral knee osteoarthritis, intra-articular infiltration of corticosteroids or hyaluronic acid in the hip for less than six months, patients with neurological diseases, peripheral neuropathy or psychiatric diseases, use of a pacemaker or Prothrombin Activity Time (INR) \> 3.